Literature DB >> 12114409

Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.

Marina Parton1, Stanislaw Krajewski, Ian Smith, Maryla Krajewska, Caroline Archer, Mihikito Naito, Roger Ahern, John Reed, Mitchell Dowsett.   

Abstract

PURPOSE: Induction of apoptosis is a key factor in the response of tumors to chemotherapy. Laboratory studies have established many of the factors that regulate and execute apoptosis, but the significance of these in human tumors is poorly understood. Therefore, the relationship between key components of this machinery was examined in primary human breast carcinomas before and 24 h after the initiation of chemotherapy. EXPERIMENTAL
DESIGN: Apoptosis was measured using the terminal deoxynucleotidyl transferase-mediated nick end labeling assay, and proliferation was assessed using the anti-Ki67 antibody MIB-1. Monospecific polyclonal antibodies were used for immunohistochemical detection of Bcl-2, Bax, XIAP, activated (cleaved) caspase 3 and 6, and cleaved DNA Fragmentation Factor-40 (DFF40) using paraffin-embedded tissues.
RESULTS: Before treatment, a significant correlation was found between apoptosis and proliferation (r = 0.64, P < 0.0001), between caspases 3 and 6 (r = 0.49, P = 0.004) and between cleaved DFF40 and active caspases 3 (r = 0.66, P < 0.0001) or 6 (r = 0.47, P = 0.006). Before treatment, expression of inhibitor of apoptosis protein, XIAP, also correlated positively with cleaved caspase 3 (r = 0.64, P < 0.0001), caspase 6 (r = 0.36, P = 0.04), and DFF40 (r = 0.61, P = 0.0001). At 24 h after chemotherapy, significant increases in apoptosis and decreases in proliferation were observed, with the degree of increase in apoptosis inversely associated with decrease in proliferation. Chemotherapy-induced increases in Bax were correlated with increases in cleaved DFF40 (r = 0.54, P = 0.0008), but no other variables showed significant change at 24 h after initiation of chemotherapy.
CONCLUSION: The pretreatment biomarker relationships suggest parallel cleavage and activation of these executioner proteins in breast cancer and that XIAP may maintain cell survival in the face of caspase activation. The findings provide in vivo evidence in human breast cancer that chemotherapy induces an apoptotic program characterized by up-regulation of Bax and cleavage of caspase substrate DFF40.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114409

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

2.  Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.

Authors:  Laura M Vargas-Roig; F Darío Cuello-Carrión; Nicolás Fernández-Escobar; Pedro Daguerre; Marcela Leuzzi; Jorge Ibarra; Francisco E Gago; Silvina B Nadin; Daniel R Ciocca
Journal:  Mol Oncol       Date:  2008-01-13       Impact factor: 6.603

3.  Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.

Authors:  A K Srivastava; P K Singh; D Singh; D Dalela; S K Rath; M M Goel; M L B Bhatt
Journal:  Tumour Biol       Date:  2014-05-23

Review 4.  Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.

Authors:  Shaomeng Wang; Longchuan Bai; Jianfeng Lu; Liu Liu; Chao-Yie Yang; Haiying Sun
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-09-29       Impact factor: 2.673

Review 5.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

6.  Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.

Authors:  Jianfeng Lu; Donna McEachern; Haiying Sun; Longchuan Bai; Yuefeng Peng; Su Qiu; Rebecca Miller; Jinhui Liao; Han Yi; Meilan Liu; Anita Bellail; Chunhai Hao; Shi-Yong Sun; Adrian T Ting; Shaomeng Wang
Journal:  Mol Cancer Ther       Date:  2011-03-03       Impact factor: 6.261

7.  Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.

Authors:  L C Singh; Anurupa Chakraborty; Ashwani K Mishra; Thoudam Regina Devi; Nidhi Sugandhi; Chintamani Chintamani; Dinesh Bhatnagar; Sujala Kapur; Sunita Saxena
Journal:  Med Oncol       Date:  2011-04-29       Impact factor: 3.064

8.  A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Authors:  Monika Graeser; Afshan McCarthy; Christopher J Lord; Kay Savage; Margaret Hills; Janine Salter; Nicholas Orr; Marina Parton; Ian E Smith; Jorge S Reis-Filho; Mitch Dowsett; Alan Ashworth; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2010-08-27       Impact factor: 12.531

9.  Cytoprotective effects of IAPs revealed by a small molecule antagonist.

Authors:  Stefanie Galbán; Clara Hwang; Julie M Rumble; Karolyn A Oetjen; Casey W Wright; Alain Boudreault; Jon Durkin; John W Gillard; James B Jaquith; Stephen J Morris; Colin S Duckett
Journal:  Biochem J       Date:  2009-02-01       Impact factor: 3.857

10.  Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.

Authors:  Catalina Trejo-Becerril; Luis F Oñate-Ocaña; Lucía Taja-Chayeb; América Vanoye-Carlo; Lucely Cetina; Alfonso Duenas-Gonzalez
Journal:  BMC Cancer       Date:  2005-06-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.